Growth Hormone Axis Research Peptides

The short version

Biotide Peptides is a reading desk, not a store. It collects what the published research literature actually says about three peptides that share a common research question: how does stimulating the growth hormone axis — the signaling chain that runs from the pituitary to growth hormone to IGF-1 — affect body composition, tissue dynamics, and physiology?

A peptide is a short chain of amino acids, the same building blocks that make up proteins, only far smaller and more targeted. Each of these three has been studied because it acts on a specific receptor in the pituitary that drives GH secretion. The combination entry — CJC-1295 / Ipamorelin — is the lead because it is what most researchers mean when they discuss the GH-axis "stack"; CJC-1295 and Ipamorelin are also covered individually because they have distinct mechanisms, pharmacokinetics, and evidence bases that matter for a fair reading.

This guide does one job: it tells you, in plain language and with citations, what each compound was tested on, in which species, and how far the evidence actually reaches. None of these is an approved medicine. We do not sell anything, we do not give medical advice, and we never list a human dose.

What are research peptides?

Hormones and signaling molecules in your body are often peptides — short chains of amino acids that act like keys fitting specific locks (receptors) on the surface of cells. A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has not been approved by a regulator as a medicine.

The three compounds on this desk belong to a subcategory called growth hormone secretagogues (GHS) or GH-releasing peptides (GHRPs). Rather than supplying GH directly, they signal the pituitary to release its own GH in pulses — preserving the body's natural pulsatile GH pattern. Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished. When this site reports a number, it reports it the way the study did — for example, studied at 30 micrograms per kilogram in healthy adults — never as a recommendation.

How these three fit into GH-axis research

The three entries on this desk approach the same GH-axis question from complementary angles, which is why they sit together.

• CJC-1295 / Ipamorelin is the lead. It is a two-peptide combination: CJC-1295 (a GHRH analogue) and ipamorelin (a selective ghrelin-receptor agonist). Because the two arms act through independent pathways — GHRH receptor via cAMP and GHS-R1a via calcium — co-stimulation produces a GH pulse larger than either agent alone ^[5][7]. The combination has never been tested as a fixed blend in a controlled clinical trial; its profile is inferred from the separate component literatures.
• CJC-1295 is the GHRH-analogue half. A single subcutaneous dose in healthy adults raised mean plasma GH two- to ten-fold for six or more days and IGF-1 up to 28 days after multiple doses ^[3]. Its DAC form's chemistry — covalent albumin binding via a maleimidopropionyl linker — is the mechanism behind that multi-day half-life ^[4].
• Ipamorelin is the ghrelin-receptor half. Its defining pharmacological feature is selectivity: at doses far above its GH threshold, it does not meaningfully raise ACTH, cortisol, or prolactin, in contrast to earlier growth-hormone-releasing peptides ^[6]. Its only published human Phase 2 trial — 114 adults post-bowel-resection — missed its primary endpoint ^[14].

Together they frame the GH-axis research landscape: combined pharmacology, the GHRH-analogue arm, and the selective GHRP arm. Use the individual pages to read each in depth, or compare them side by side.

A note on how this desk reads the literature

Biotide Peptides is a cross-referenced literature digest organized like a clinician's briefing: what it is, what is shown, what to watch, what is unknown. Each page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source. Where the evidence is thin, single-lab, or preclinical, the site says so plainly — that caution is part of the record, not a footnote to it. The aim is a focused, accurate map of what the literature actually says about the GH/IGF-1 axis, so you can see where the science is solid and where the gaps are.